Clinical trial
A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.
NCT00400322 is registered in ClinicalTrials.gov with Karolinska Institutet as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.
- Lead sponsor
- Karolinska Institutet
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- June 30, 2008
- Enrollment
- 42 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cytomegalovirus infection, glioblastoma multiforme